Vedolizumab

Vedolizumab is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.

Product Specifications

CAS Number

[943609-66-3]

Product Name Alternative

Anti-Human lymphocyte α4β7 integrin, Humanized Antibody; LDP-02; MLN-002

UNSPSC

12352203

Target

Integrin

Type

Inhibitory Antibodies

Related Pathways

Cytoskeleton

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cancer

Assay Protocol

https://www.medchemexpress.com/Vedolizumab.html

Purity

99.90

Solubility

10 mM in H2O

Smiles

[Vedolizumab]

Molecular Weight

(146.868 kDa)

References & Citations

[1]Soler D, et al. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrintherapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009 Sep;330 (3) :864-75.|[2]Singh H, et al. Vedolizumab: A novel anti-integrin drug for treatment of inflammatory bowel disease. J Nat Sci Biol Med. 2016 Jan-Jun;7 (1) :4-9.